See today's BioWorld Asia
To read the full story, subscribe or sign in.

CSL’s Seqirus snags $30M contract with BARDA to develop pandemic avian flu vaccines

Oct. 11, 2022
By Tamra Sami
CSL Ltd. subsidiary Seqirus inked a $30.1 million deal with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and evaluate two influenza A subtype H2Nx (avian flu) vaccines in a phase I trial.
BioWorld Asia Deals and M&A Infection Vaccine BARDA